Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Cascadian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cascadian Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cascadian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cascadian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cascadian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Cascadian Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Adimab Enters into Agreement with Oncothyreon 11
Licensing Agreements 12
Oncothyreon Enters into Licensing Agreement with Array BioPharma for ONT-380 12
Sentinel Oncology Enters Into Licensing Agreement With Oncothyreon To Develop Chk1 Inhibitors 13
Braeburn Pharma Enters into Licensing Agreement with Oncothyreon 14
Equity Offering 15
Cascadian Therapeutics Plans to Raise up to USD250 Million in Public Offering of Shares 15
Cascadian Therapeutics Raises USD87.97 million in Public Offering of Shares 16
Cascadian Therapeutics Raises USD6 Million in Public Offering of Series E Preferred Stock 18
Cascadian Therapeutics Raises USD32.2 Million in Public Offering of Shares 20
Cascadian Therapeutics Raises USD13.8 Million in Private Placement of Shares 22
Oncothyreon to Raise up to USD50 Million in Public Offering of Shares 24
Oncothyreon Prices Public Offering of Shares for USD20 Million 25
Oncothyreon Prices Public Offering of Preferred Shares for USD2 Million 27
Oncothyreon Raises USD20 Million in Public Offering of Preferred Shares 29
Oncothyreon Raises USD23 Million in Public Offering of Shares 31
Oncothyreon Raises USD16.6 million Public Offering Of Common Stock 33
Oncothyreon Completes Private Placement Of Units For US$10 Million 34
Oncothyreon Completes Public Offering Of Common Stock For US$54 Million 35
Acquisition 37
Seattle Genetics Acquires Cascadian Therapeutics for USD614 Million in Tender Offer 37
Oncothyreon Acquires Alpine Biosciences for USD27 Million 39
Cascadian Therapeutics Inc – Key Competitors 40
Cascadian Therapeutics Inc – Key Employees 41
Cascadian Therapeutics Inc – Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Recent Developments 43
Financial Announcements 43
Nov 08, 2017: Cascadian Therapeutics Reports Third Quarter 2017 Financial Results 43
Aug 08, 2017: Cascadian Therapeutics Reports Second Quarter 2017 Financial Results 45
Mar 09, 2017: Cascadian Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results 46
Corporate Communications 47
Dec 13, 2017: Cascadian Therapeutics Added to the Nasdaq Biotechnology Index 47
Mar 13, 2017: Cascadian Therapeutics Announces Changes to Board of Directors 48
Other Significant Developments 49
Jan 05, 2017: Cascadian Therapeutics Announces 2017 Outlook and Recent Drug Portfolio Progress 49
Appendix 51
Methodology 51
About GlobalData 51
Contact Us 51
Disclaimer 51
Cascadian Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Cascadian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cascadian Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cascadian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cascadian Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Cascadian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Adimab Enters into Agreement with Oncothyreon 11
Oncothyreon Enters into Licensing Agreement with Array BioPharma for ONT-380 12
Sentinel Oncology Enters Into Licensing Agreement With Oncothyreon To Develop Chk1 Inhibitors 13
Braeburn Pharma Enters into Licensing Agreement with Oncothyreon 14
Cascadian Therapeutics Plans to Raise up to USD250 Million in Public Offering of Shares 15
Cascadian Therapeutics Raises USD87.97 million in Public Offering of Shares 16
Cascadian Therapeutics Raises USD6 Million in Public Offering of Series E Preferred Stock 18
Cascadian Therapeutics Raises USD32.2 Million in Public Offering of Shares 20
Cascadian Therapeutics Raises USD13.8 Million in Private Placement of Shares 22
Oncothyreon to Raise up to USD50 Million in Public Offering of Shares 24
Oncothyreon Prices Public Offering of Shares for USD20 Million 25
Oncothyreon Prices Public Offering of Preferred Shares for USD2 Million 27
Oncothyreon Raises USD20 Million in Public Offering of Preferred Shares 29
Oncothyreon Raises USD23 Million in Public Offering of Shares 31
Oncothyreon Raises USD16.6 million Public Offering Of Common Stock 33
Oncothyreon Completes Private Placement Of Units For US$10 Million 34
Oncothyreon Completes Public Offering Of Common Stock For US$54 Million 35
Seattle Genetics Acquires Cascadian Therapeutics for USD614 Million in Tender Offer 37
Oncothyreon Acquires Alpine Biosciences for USD27 Million 39
Cascadian Therapeutics Inc, Key Competitors 40
Cascadian Therapeutics Inc, Key Employees 41
Cascadian Therapeutics Inc, Subsidiaries 42
List of Figures
Cascadian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cascadian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cascadian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cascadian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cascadian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cascadian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Cascadian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cascadian Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9